Drug intelligence / Profile preview

cidabenamine

Development stage: Phase 3
Modality: Small Molecules

Overview

Cidabenamine is a highly selective histone deacetylase (HDAC) inhibitor, with specificity for HDAC subtypes 1, 2, 3, and 10. HDAC inhibitors function by blocking the activity of histone deacetylases—enzymes that remove acetyl groups from lysine residues on histones and other proteins. This inhibition leads to increased acetylation of histones, resulting in altered gene expression and potential anti-tumor effects. Cidabenamine's selectivity distinguishes it from pan-HDAC inhibitors by targeting specific HDAC isoforms implicated in cancer biology[7].

Brand names: Epidaza爱谱沙
Other names: 西达本胺

Targets

HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)

Beyond the preview

Go deeper on cidabenamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cidabenamine.

Explore the full profile